KR20220093141A - Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3) - Google Patents

Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3) Download PDF

Info

Publication number
KR20220093141A
KR20220093141A KR1020227017380A KR20227017380A KR20220093141A KR 20220093141 A KR20220093141 A KR 20220093141A KR 1020227017380 A KR1020227017380 A KR 1020227017380A KR 20227017380 A KR20227017380 A KR 20227017380A KR 20220093141 A KR20220093141 A KR 20220093141A
Authority
KR
South Korea
Prior art keywords
antibody
seq
region
ser
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227017380A
Other languages
English (en)
Korean (ko)
Inventor
마이클 버제스
크리스틴 헤게
카우시크 다타
아이작 보스
민 디엠 뷰
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20220093141A publication Critical patent/KR20220093141A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227017380A 2019-11-05 2020-11-04 Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3) Pending KR20220093141A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP19207293.2 2019-11-05
EP20179573 2020-06-11
EP20179573.9 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (1)

Publication Number Publication Date
KR20220093141A true KR20220093141A (ko) 2022-07-05

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017380A Pending KR20220093141A (ko) 2019-11-05 2020-11-04 Bcma 및 cd3에 대한 항체 치료 방법(methods of treatment with antibodies against bcma and cd3)

Country Status (11)

Country Link
US (1) US20230057602A1 (enExample)
EP (1) EP4054725A4 (enExample)
JP (1) JP7792333B2 (enExample)
KR (1) KR20220093141A (enExample)
CN (1) CN115279459A (enExample)
AU (1) AU2020379757A1 (enExample)
BR (1) BR112022008516A2 (enExample)
CA (1) CA3160137A1 (enExample)
IL (1) IL292704A (enExample)
MX (1) MX2022005292A (enExample)
WO (1) WO2021092056A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
KR102745676B1 (ko) 2016-12-21 2024-12-24 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
SI3819007T1 (sl) 2019-11-11 2024-10-30 Amgen Inc. Režim odmerjanja sredstev proti BCMA
CN119569887A (zh) * 2021-06-24 2025-03-07 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
WO2025042742A1 (en) * 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
WO2025059362A1 (en) 2023-09-13 2025-03-20 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
WO2025117764A1 (en) * 2023-12-01 2025-06-05 Teneoone, Inc. Methods for the treatment of multiple myeloma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738568C (en) * 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
AU2016302881B2 (en) * 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
EP3535295A1 (en) * 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
KR20190074300A (ko) * 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약

Also Published As

Publication number Publication date
AU2020379757A1 (en) 2022-05-26
US20230057602A1 (en) 2023-02-23
WO2021092056A1 (en) 2021-05-14
JP7792333B2 (ja) 2025-12-25
EP4054725A1 (en) 2022-09-14
CA3160137A1 (en) 2021-05-14
CN115279459A (zh) 2022-11-01
MX2022005292A (es) 2022-08-10
EP4054725A4 (en) 2024-01-10
JP2022553822A (ja) 2022-12-26
IL292704A (en) 2022-07-01
BR112022008516A2 (pt) 2022-08-30

Similar Documents

Publication Publication Date Title
JP7792333B2 (ja) Ｂｃｍａおよびｃｄ３に対する抗体を用いる処置方法
KR102364383B1 (ko) 삼중-특이적 결합 분자 및 그것의 사용 방법
CN110167964B (zh) 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
JP7783183B2 (ja) 自己免疫障害における抗ｂｃｍａ治療
US20220372156A1 (en) Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
US11987636B2 (en) Dosing of a bispecific antibody that binds CD20 and CD3
JP2021513961A (ja) 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
WO2021092060A1 (en) Methods of treatment
JP2021505637A (ja) 二重特異性ｃｄ１６結合分子、及び疾患の治療におけるその使用
WO2020041404A1 (en) Pd-l1-binding molecules and use of the same for the treatment of disease
IL254335B (en) Isolated peptides derived from the dimerization regions of b7
US20230172923A1 (en) Methods of treating cytokine-related adverse events
EA049790B1 (ru) Способы лечения антителами к bcma и cd3
HK40083315A (en) Methods of treatment with antibodies against bcma and cd3
WO2025042742A1 (en) Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
EA050324B1 (ru) Терапия антителами против bcma при аутоиммунных расстройствах
WO2025217101A2 (en) Agonistic anti-il-2rbg heavy‑chain antibodies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000